2019’s ACT meeting in Phoenix, AZ was the 40th Annual Meeting and brought some key highlights to the Lovelace Biomedical team. In addition to catching up with colleagues, scientists and business development team members had the opportunity to attend continuing education courses and scientific sessions in toxicology.
In reviewing highlights with the scientific staff, several highlights came up. Jacob McDonald saw the attendance and breadth of the meeting as a highlight this year. He stated,
“The program sessions within cell and gene therapy were very well attended and included scientific presentations within the design and conduct of toxicology studies for cell and gene therapy.”
A key summary within all the sessions on cell and gene therapy was the need to leverage an experience team and to design programs as fit for purpose as there is no standard template! Philip Kuehl attended the continuing education course on new Nonclinical ICH Guidance and spoke highly of the highlights on the nonclinical safety testing in support of pediatric medicines. Many therapeutics are developed for an adult indication first with pediatric approval following. This CE provided information on the toxicology study design strategies when the pediatric indication is the primary indication.
The Lovelace Biomedical business development team highlighted the meetings attendance and the interplay between the scientific sessions and sponsors which continues to make this meeting a leader for scientific teaming. Consider reaching out to Lovelace Biomedical for any of your toxicology needs.
By Philip Kuehl, Senior Scientist, Director of Scientific Core Labs
